Protective effect and duration of action of formoterol aerosol on exercise-induced asthma
- PMID: 1677894
Protective effect and duration of action of formoterol aerosol on exercise-induced asthma
Abstract
The short-term protective effect on exercise-induced asthma (EIA) and the duration of action of formoterol, given by metered dose aerosol at a dose of 24 micrograms, were compared with salbutamol (200 micrograms) and placebo in twelve asthmatic EIA-positive patients in a double-blind, placebo-controlled, three period cross-over study. On each treatment day the patients were given one of the drugs or placebo and two exercise tests were performed at the second and at the eighth hour after dosing. Using a standard procedure, exercise was performed by treadmill in well-controlled environmental conditions. In the first test at 2 h a significant difference relative to placebo (p less than 0.001) at each incremental time after exercise (i.e. 5, 10, 15, 20, 30 min) was obtained with both formoterol and salbutamol, without any significant difference between formoterol and salbutamol. After the eighth hour test formoterol still protected against EIA in comparison to both salbutamol and placebo. The effect of salbutamol at this time was not different from placebo. No adverse effects were reported in any treatment group. Formoterol has a long duration of action in protecting against EIA that persisted for eight hours, removing the need to dose with beta 2-agonist before every exercise.
Similar articles
-
Inhaled formoterol in the prevention of exercise-induced bronchoconstriction in asthmatic children.Am J Respir Crit Care Med. 1994 Apr;149(4 Pt 1):935-9. doi: 10.1164/ajrccm.149.4.7908246. Am J Respir Crit Care Med. 1994. PMID: 7908246 Clinical Trial.
-
Protective effect and duration of action of inhaled formoterol and salbutamol on exercise-induced asthma in children.J Allergy Clin Immunol. 1992 Jun;89(6):1176-82. doi: 10.1016/0091-6749(92)90302-i. J Allergy Clin Immunol. 1992. PMID: 1351489 Clinical Trial.
-
Formoterol provides long-lasting protection against exercise-induced bronchospasm.Ann Allergy Asthma Immunol. 2002 Oct;89(4):407-12. doi: 10.1016/S1081-1206(10)62043-1. Ann Allergy Asthma Immunol. 2002. PMID: 12392386 Clinical Trial.
-
The use of inhaled formoterol in the treatment of asthma.Ann Allergy Asthma Immunol. 2006 Jul;97(1):24-33. doi: 10.1016/S1081-1206(10)61365-8. Ann Allergy Asthma Immunol. 2006. PMID: 16892777 Review.
-
Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.J Asthma. 2010 May;47(4):447-59. doi: 10.3109/02770901003725684. J Asthma. 2010. PMID: 20528601 Review.
Cited by
-
Long-acting beta 2-adrenoceptor agonists and exercise-induced asthma: lessons to guide us in the future.Paediatr Drugs. 2004;6(3):161-75. doi: 10.2165/00148581-200406030-00003. Paediatr Drugs. 2004. PMID: 15170363 Review.
-
Beta2-agonists for asthma: the pediatric perspective.Clin Rev Allergy Immunol. 2006 Oct-Dec;31(2-3):209-18. doi: 10.1385/CRIAI:31:2:209. Clin Rev Allergy Immunol. 2006. PMID: 17085794 Review.
-
Long- versus short-acting beta 2-agonists. Implications for drug therapy.Drugs. 1994 Feb;47(2):207-22. doi: 10.2165/00003495-199447020-00001. Drugs. 1994. PMID: 7512898 Review. No abstract available.
-
Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma.Drugs. 1998 Feb;55(2):303-22. doi: 10.2165/00003495-199855020-00016. Drugs. 1998. PMID: 9506248 Review.
-
Beta₂-agonists for exercise-induced asthma.Cochrane Database Syst Rev. 2013 Oct 2;2013(10):CD003564. doi: 10.1002/14651858.CD003564.pub3. Cochrane Database Syst Rev. 2013. PMID: 24089311 Free PMC article.